Related Experiment Video
Updated: Jun 3, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
Promotion of beta cell proliferation through DYRK kinase inhibition using the marine natural product breitfussin C
Sara Ullsten1, Kine Østnes Hansen1, Guillaume Axel Petit1
1MARBIO, UiT - The Arctic University of Norway, Breivika, 9037, Tromsø, Norway.
Abstract:
Pro-inflammatory cytokines, like interleukin-1 beta and interferon gamma, are known to activate signalling pathways causing pancreatic beta cell death and dysfunction, contributing to the onset of diabetes. Targeting cytokine signalling pathways offers a potential strategy to slow or even halt disease progression, reducing reliance on exogenous insulin and improving glucose regulation. This study explores the protective and proliferative effects of breitfussin C (BfC), a natural compound isolated from the Arctic marine hydrozoan Thuiaria breitfussi, on pancreatic beta cells exposed to pro-inflammatory cytokines. Using the beta cell line RIN-M5F, we assessed the protective effects of BfC through a MTS assay for cell viability, caspase 3/7 activity for apoptosis, and EdU incorporation and cell cycle distribution for proliferation. Additionally, we investigated BfC's inhibitory effects on the DYRK family of kinases using kinase activity and binding assays, western blotting, and docking simulations. Our findings reveal that BfC treatment effectively increases beta cell proliferation and counteracts cytokine-induced decrease in proliferation. The proliferative effect is associated with inhibition of DYRK kinases and a subsequent decrease in the cell cycle inhibitor p27KIP. These results suggest that BfC mediates beta cell-protective effect by promoting proliferation through DYRK inhibition, highlighting its potential as a molecular starting point for the development of a therapeutic agent against diabetes.
Insights
Breitfussin C protects pancreatic beta cells from cytokine damage and promotes proliferation by inhibiting DYRK kinases. This natural compound shows potential for developing new diabetes therapies.
Area of Science:
- Endocrinology
- Molecular Biology
- Marine Pharmacology
Background:
- Pro-inflammatory cytokines induce pancreatic beta cell death and dysfunction, contributing to diabetes onset.
- Targeting cytokine signaling pathways is a potential therapeutic strategy for diabetes.
- Breitfussin C (BfC) is a natural compound from Thuiaria breitfussi with potential beta cell protective effects.
Purpose of the Study:
- To investigate the protective and proliferative effects of breitfussin C (BfC) on pancreatic beta cells exposed to pro-inflammatory cytokines.
- To explore the mechanism of BfC's action, including its effects on DYRK kinases and cell cycle regulation.
Main Methods:
- Utilized the beta cell line RIN-M5F for experiments.
- Assessed cell viability (MTS assay), apoptosis (caspase 3/7 activity), and proliferation (EdU incorporation, cell cycle distribution).
- Investigated BfC's inhibition of DYRK kinases using biochemical assays, western blotting, and docking simulations.
Main Results:
- BfC treatment significantly increased beta cell proliferation and counteracted cytokine-induced proliferation reduction.
- BfC inhibited DYRK kinases, leading to decreased levels of the cell cycle inhibitor p27KIP.
- BfC demonstrated a protective effect on beta cells against cytokine-induced damage.
Conclusions:
- Breitfussin C promotes pancreatic beta cell proliferation via DYRK kinase inhibition.
- BfC's mechanism involves downregulating the cell cycle inhibitor p27KIP.
- BfC represents a potential therapeutic starting point for diabetes treatment by enhancing beta cell function and survival.
More Related Videos
Related Concept Videos
Cell Specific Gene Expression
Insulin Secretory Vesicles
Inhibition of Cdk Activity
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...

